Karyopharm Therapeutics (KPTI) Common Equity (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Common Equity came in at -$292.9 million in Q4 2025, down 57.47% YoY from -$688.8 million in Q4 2024, and down 8.79% on a QoQ basis from -$269.3 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Common Equity (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Common Equity data on file, last reported at -$292.9 million in Q4 2025.
- Quarterly Common Equity fell 57.47% year-over-year to -$292.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$292.9 million (down 57.47% YoY) and the FY2025 annual result came in at -$292.9 million, down 57.47% from the prior year.
- Common Equity declined to -$292.9 million in Q4 2025, from -$269.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of -$16.7 million in Q4 2022 to a low of -$292.9 million in Q4 2025.
- A 5-year average of -$134.6 million and a median of -$129.1 million in 2021 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity surged 79.09% — and 2023, when it plunged 717.76%.
- Tracing KPTI's Common Equity over 5 years: stood at -$79.7 million in 2021, then surged by 79.09% to -$16.7 million in 2022, then sank by 717.76% to -$136.2 million in 2023, then tumbled by 36.57% to -$186.0 million in 2024, then slumped by 57.47% to -$292.9 million in 2025.
- The last three Common Equity figures came in at -$292.9 million (Q4 2025), -$269.3 million (Q3 2025), and -$238.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | 9.79 Bn |
| 10 | Karyopharm Therapeutics | 53.54 Mn | 53.54 Mn | 32.35 Mn | -330.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -330.17 Mn |
| Dec 31, 2025 | -292.93 Mn |
| Sep 30, 2025 | -269.26 Mn |
| Jun 30, 2025 | -238.93 Mn |
| Mar 31, 2025 | -205.88 Mn |
| Dec 31, 2024 | -186.02 Mn |
| Sep 30, 2024 | -159.65 Mn |
| Jun 30, 2024 | -132.14 Mn |
| Mar 31, 2024 | -168.96 Mn |
| Dec 31, 2023 | -136.21 Mn |
| Sep 30, 2023 | -100.40 Mn |
| Jun 30, 2023 | -71.25 Mn |
| Mar 31, 2023 | -45.17 Mn |
| Dec 31, 2022 | -16.66 Mn |
| Sep 30, 2022 | -140.28 Mn |
| Jun 30, 2022 | -116.34 Mn |
| Mar 31, 2022 | -83.08 Mn |
| Dec 31, 2021 | -79.67 Mn |
| Sep 30, 2021 | -125.98 Mn |
| Jun 30, 2021 | -83.13 Mn |